



(51) International Patent Classification:

A01N 63/00 (2006.01) A61K 35/35 (2015.01)
A01N 65/00 (2009.01)

(21) International Application Number:

PCT/US2014/063250

(22) International Filing Date:

30 October 2014 (30.10.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/962,068 30 October 2013 (30.10.2013) US

(71) Applicants: **THE CURATORS OF THE UNIVERSITY OF MISSOURI** [US/US]; 316 University Hall, Columbia, MO 65211 (US). **PEOPLE FOR THE ETHICAL TREATMENT OF ANIMALS** [US/US]; 501 Front Street, Norfolk, VA 23510 (US).

(72) Inventors: **GENOVESE, Nicholas, J.**; University of Missouri, 263a Bond Life Science Center, Columbia, MO 65211 (US). **ROBERTS, R., Michael**; University of Missouri, 240b Bond Life Science Center, Columbia, MO 65211 (US). **TELUGU, Bhanu, Prakash, V., L.**; University of Maryland - College Park, Dept. of Animal and Avian Sciences, College Park, MD 20742 (US).

(74) Agents: **HOLTZ, William, A.** et al.; One US Bank Plaza, St. Louis, MO 63101 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: METHOD FOR SCALABLE SKELETAL MUSCLE LINEAGE SPECIFICATION AND CULTIVATION



DOX = Doxycycline ; E2 = 17 β -Estradiol; TRE = Tetracycline Responsive Element;
rTA = tetracycline transactivator; MBS = MyoD Binding Site

(57) Abstract: The present disclosure relates to methods for enhancing cultured meat production, such as live-stock-autonomous meat production. In certain aspects, the meat is any metazoan tissue or cell-derived comestible product intended for use as a comestible food or nutritional component by humans, companion animals, domesticated or captive animals whose carcasses are intended for comestible use, service animals, conserved animal species, animals used for experimental purposes, or cell cultures.

FIG. 3

METHOD FOR SCALABLE SKELETAL MUSCLE LINEAGE SPECIFICATION AND CULTIVATION

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Patent Application No. 61/962,068, filed October 30, 2013, which is incorporated herein by reference in its entirety.

INCORPORATION OF SEQUENCE LISTING

[0002] The content of the electronically submitted sequence listing in ASCII text file (Name 52553_136621_ST25.txt; Size: 2,962 bytes; and Date of Creation: October 30, 2014) filed with the application is incorporated herein by reference in its entirety.

STATEMENT REGARDING FEDERALLY-SPONSORED RESEARCH AND DEVELOPMENT

[0003] This invention was made with Government support under Grant No. R01 HD069979/00032722 awarded by the National Institutes of Health. The Government has certain rights in the invention.

BACKGROUND

[0004] The present disclosure relates to methods for enhancing cultured meat production, such as livestock-autonomous meat production. The conceptual promises of “cultured meat” (e.g., animal-autonomous meat production by *in vitro* cell culture, tissue engineering, and food technology methods) include increased production efficiency, reduced environmental impacts, expanded culinary application utility, enhanced nutritional value, cruelty-free production and improved food safety relative to conventionally produced meats. Technologies, to date however, have not advanced sufficiently to support scalable, economically sustainable production. The current laboratory-scale cultivation of prototype tissues has utilized primary animal components such as animal tissues and serum, thereby largely negating the advantages of animal-autonomous meat production. Hence, current methods fail to resolve the animal

- 2 -

dependence from cultured meat production sufficiently to realize the conceptual promises of “cultured meat” and provide a commercially advantageous product. Therefore, there is a need to provide new and improved methods for scalable meat cultivation from a self-renewing source *in vitro* for dietary nutrition and other applications.

SUMMARY

[0005] The example embodiments provide a scalable platform for skeletal muscle cultivation that utilizes cell lines with the potential to differentiate as skeletal muscle. In certain aspects, the cell lines are from livestock such as domestic cattle, pigs, sheep, goats, camels, water buffalo, rabbits and the like. In certain aspects, the cells lines are from poultry such as domestic chicken, turkeys, ducks, geese, pigeons and the like. In certain aspects, the cell lines are from common game species such as wild deer, gallinaceous fowl, waterfowl, hare and the like. In certain aspects, the cell lines are from aquatic species or semi-aquatic species harvested commercially from wild fisheries or aquaculture operations, or for sport, including certain fish, crustaceans, mollusks, cephalopods, cetaceans, crocodilians, turtles, frogs and the like. In certain aspects, the cell lines are from exotic, conserved or extinct animal species. In certain aspects, the cell lines are from any metazoan species demonstrating the capacity for skeletal muscle tissue specification. In certain aspects, the cell lines are for research or for therapeutic purposes, such as humans, primates, rodents including rats and mice, and companion animals such as dogs, cats, horses, and the like. In certain specific aspects, the cell lines from any organisms are self-renewing stem cell lines. In certain aspects, the selected cell line is modified by a ‘genetic switch’ to induce rapid and efficient conversion of cells to skeletal muscle for cultured meat production. In an example embodiment, the above or other aspects may be accomplished by a method comprising modifying a selected self-renewing cell line by a myogenic transcription factor to produce a myogenic-transcription-factor-modified cell line, and inducing such modified cell line by exogenous regulation to direct alternate self-renewal or differentiation processes.

[0006] In certain aspects, the self-renewing cell line is selected from a group consisting of embryonic stem cells, induced pluripotent stem cells, somatic cell lines, or extra-embryotic cell lines with myogenic potential. In certain aspects, the cell line is derived from species intended for dietary consumption. Illustrative, non-limiting examples of

- 3 -

myogenic transcription factors include, alone or in combination, MYOD1, MYOG, MYF5, MYF6, PAX3, PAX7, paralogs, orthologs, genetic variants thereof, or transcriptional activation agonists of the respective promoter recognition DNA sequences of the myogenic transcription factors as further described herein.

[0007] In certain specific aspects, an inducible MyoD transcription factor may be used as the differentiation lineage specifier. In certain specific aspects, the porcine induced pluripotent cell line O2K may be employed as the self-renewing cell line. In one specific aspect the method comprises modifying a O2K stem cell line with an inducible MyoD transcription factor to produce a myogenic-transcription-factor-modified O2KM cell line, and inducing such O2KM cell line by exogenous regulation to direct self-renewal or differentiation processes. The aforementioned modifying step can further comprise modifying the cell line with a chromosomally integrated vector constitutively expressing an inducible fusion of the MYOD1 transcription factor and an ESR1 ligand binding domain from a constitutively active promoter region. For example, the inducible activity of the translated fusion transcript (e.g., MyoDER), can be conditionally activated in the presence of the ESR1 agonist (e.g., 17- β Estradiol (E2)).

[0008] In certain aspects, the inducing step can further comprise the self-renewal sub-step and the differentiation sub-step regulated by a double-switch mechanism. In the self-renewal sub-step, the modified cell line undifferentiated ground-state is preserved, such as in the presence of doxycycline (DOX), whereby the cell line is maintained in a stem cell self-renewal state by the induced expression of the pluripotency transgenes *POU5F1* and *KLF4*. In the differentiation sub-step, the modified cell line is treated, such as with E2 in the absence of DOX, whereas the cell line is efficiently specified to skeletal myocytes, i.e., the myogenic lineage, by the inducible MyoD transcription factor, resulting in characteristic elongated cells with spindle-like morphology. When further cultured in low-mitogen culture medium, the derivative myocytes can fuse into multinucleated myotubes, precursors to skeletal muscle fibers. Following extended culture in low-mitogen medium, the multinucleated myotubes mature into skeletal muscle fibers capable of terminal differentiation, as evidenced by increased expression of MYOG, DES, MYHC; fusion; and development of sarcomeric myofibrils with contractile potential. The differentiation sub-step can further comprise adding certain reagents in the culture medium for activating the canonical WNT signaling pathway to prevent cell death

- 4 -

and facilitate myogenic differentiation, and adding epigenetic modulators to the culture medium to alter the chromatin structure for enhanced myogenic gene expression.

[0009] Certain aspects of the disclosure employ genetically enhanced cells for unlimited renewal capacity and efficient conversion to skeletal muscle, the predominant tissue lineage constituting non-offal meat products, in serum-free culture medium. When coupled with a scalable tissue engineering approach, such methods can revolutionize the way meat is produced and marketed for consumers by enabling cultivation of animal tissue in unlimited quantities for animal-autonomous cultured meat production. Additional applications contemplated include *in vivo* xeno-transplantation use and *in vitro* models for drug screening, developmental physiology, and developmental biology.

[0010] Further features and advantages of the disclosure, as well as the structure and operation of various embodiments of the disclosure, are described in detail below with reference to any accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS/FIGURES

[0011] Figure 1. Figure 1 shows a MyoDER DNA sequence.

[0012] Figure 2. Figure 2 is a schematic illustration of a method comprising a double-switch regulation mechanism for expansion of the undifferentiated cell line, or skeletal muscle lineage specification.

[0013] Figure 3. Figure 3 is a schematic illustration showing a double-switch mechanism applied to the myogenic modified O2KM cell line regulated by DOX or E2.

[0014] Figure 4A. Figure 4A is a schematic illustration of the selectable MyoDER transgene expression cassette. Arrows and boxes respectively indicate promoter and gene sequences.

[0015] Figure 4B. Figure 4B shows Western blot image detection of MyoDER transgene expression in blastidicin-selected O2K by an anti-MYOD1 antibody. Transgene expression cassette modified O2K is designated as O2KM. TUBA (alpha-tubulin) is detected as an internal loading control.

[0016] Figure 5. Figure 5 is an image showing O2KM cells exhibiting stable, compact-colony morphology in self-renewal conditions as the parental O2K cell line.

[0017] Figure 6. Figure 6 is a panel of images showing O2KM cultured on Poly-D-Lysine + Laminin + MATRIGEL coated dishes +/- 0.25 μ M 5-Aza-Cytidine (5AC) for

phenol-free self-renewal medium (SRM) under 5% O₂ for three days followed with or without 17- β Estradiol (E2) induction of the MyoDER fusion protein under 20% O₂ for two days in phenol red-free myogenic induction medium (MIM) supplemented with 3 μ M CHIR99021. C. Phase-contrast images of O2KM on E2-induction day 2.

- [0018] Figure 7. Figure 7 shows Western blot analysis of MYOD1 (MyoD), MYF5 (Myf5), and MYOG (myogenin) in differentiated O2KM cell lysates harvested following indicated 2-day E2 induction regimens. MyoDER migration: ~75 kD. Expected endogenous MYOD1 migration: 45-50 kD.
- [0019] Figure 8. Figure 8 shows images of immunofluorescent detection of myocyte cell surface marker NCAM (Alexa568) and nuclei (DAPI) in 5AC-exposed O2KM cultures prior to, and following, a 2-day 10 μ M E2 induction time-course.
- [0020] Figure 9. Figure 9 shows a panel of phase-contrast images of i. ground state undifferentiated O2K colonies cultured on Poly-D Lysine + Gelatin + Laminin under 5% O₂ in SRM, ii. – vi. adherent colonies differentiating from the ground state, as shown in panel i. for two days in differentiation medium (DM) under 20% O₂ supplemented with ii. 0 μ M, iii. 1 μ M, iv. 3 μ M, v. 6 μ M or vi. 9 μ M CHIR99021. Non-adherent colonies were prevalent as embryoid bodies in cultures exposed to 6 μ M (vii.) or 9 μ M (viii.) CHIR99021.
- [0021] Figure 10. Figure 10 shows a bar graph illustrating adherent O2K cell population change during differentiation. Percentages represent the ratio of adherent cells enumerated in cultures following two days in the presence of CHIR99021 at the concentrations indicated (shown in FIG. 9, panels ii.-vi.) relative to the adherent cells enumerated prior to differentiation from the ground-state (shown in FIG. 9, panel i.). n = 3 for each enumerated culture condition.
- [0022] Figure 11. Figure 11 shows a bar graph of flow cytometric analysis of Annexin V labeled cells. Undifferentiated O2K colonies were cultured under 20% O₂ in differentiation medium the presence of 0, 1, 3 or 6 μ M CHIR99021 for one day prior to analysis.
- [0023] Figure 12. Figure 12 shows Western Blot analysis of relative CTNNB1 (β -catenin) levels and phosphorylation (p-CTNNB1) at GSK3 β substrates serine 33, 37 and threonine 41 in cultures differentiated from the ground-state (as shown in FIG. 9) in the presence of CHIR99021 at the concentrations indicated. Cultures were exposed to 50 nM

Calyculin A and 30 μ M MG-132 for 3 hours prior to harvest to stabilize detectable levels of p-CTNNB1 for comparative analysis.

- [0024] Figure 13A. Figure 13A shows a graph illustrating the densitometric ratios of p-CTNNB1/CTNNB1 bands as shown in Figure 12.
- [0025] Figure 13B. Figure 13B shows a graph illustrating the densitometric ratios of CTNNB1/TUBA bands as shown in Figure 12.
- [0026] Figure 14. Figure 14 shows an image illustrating the differentiation marker time-course Western blot analysis. Expression levels of pluripotency markers, POU5F1 and KLF4, and the pre-myogenic paraxial mesoderm marker PAX3 in O2K cultures differentiated from the ground state in the presence of CHIR99021.
- [0027] Figure 15. Figure 15 shows images of terminal differentiation of O2KM myocytes differentiated in the absence (left panel) or presence (right panel) of 5-Aza-Cytidine (5AC). Note the myocyte derivatives with flattened morphology in the left panel (-5AC) in contrast to the elongated, multinucleated myotubes in the left panel (+5AC).
- [0028] Figure 16. Figure 16 shows Annexin V labeling of apoptotic cells prior to, and following 24h transition of cultures, as in Figure 9, panels i-ii.
- [0029] Figure 17A. Figure 17A shows Western blot detection of full-length CPP32 (~32 kD procaspase 3a) and the large cleaved fragment (~17kD cleaved-caspase 3a) in ground-state colonies prior to (0h) and following (12-48h) differentiation milieu transition (12-48h).
- [0030] Figure 17B. Figure 17B shows Western blot detection of full-length CPP32 and the cleaved fragment in colonies following 42h transition to the differentiation milieu in the presence of CHIR99021 levels indicated.
- [0031] Figure 18. Figure 18 shows outgrowth morphology of embryoid bodies formed in a differentiation milieu containing 6 μ M CHIR99021 for two days and following transfer to a Poly-D Lysine + Laminin + MATRIGEL coated substrate for one (d3, *left panel*) or three (d5, *right panel*) additional days.
- [0032] Figure 19A. Figure 19A shows Western Blot of lysates from unmodified piPSC cultured in the absence of 3i, DOX, hLIF and E2 in differentiation milieu containing KOSR.

- [0033] Figure 19B. Figure 19B shows Western Blot of lysates from MyoDER-modified piPSC cultured in the presence of DOX, LIF and 3i. MYODER-modified piPSC were cultured 3 days in self-renewal or expansion milieu.
- [0034] Figure 20A. Figure 20A is a schematic of the O2KM expansion and induction regimens, followed by the terminal differentiation regimen.
- [0035] Figure 20B. Figure 20B shows myotube morphology and conformation. Post-induction (d2), piPSC developed as elongated, anisotropic, refractive myotubes when exposed to 5AC during the expansion and induction regimens.
- [0036] Figure 20C. Figure 20C shows uniform expression of myosin heavy chain by d6.
- [0037] Figure 20D. Figure 20D shows myotube multinucleation. *Left panel*: enlarged image of d4 terminal differentiation cultures. Bracketed arrows indicate multiple nuclei within a single myotube. *Right panel*: myonuclei distribution by myotube ploidy by propidium iodide labeling and flow cytometry analysis. $n = 3$ with standard deviation shown.
- [0038] Figure 20E. Figure 20E Western blots show increasing expression of desmin (DES) and myogenin (MYOG) over the 8d course.
- [0039] Figure 20F. Figure 20F shows cell-cycle withdrawal concomitant with terminal differentiation.
- [0040] Figure 20G. Figure 20G shows Transmission Electron Microscopy of d6 myotubes. Sarcomeric structural units were aligned in single (*left panels*) and staggered, parallel rows (*right panel*).
- [0041] Figure 21A. Figure 21A shows asynchronous, single-cell transient cycles (*left, middle and right panels*) were observed in spontaneously contracting d6 myotube subpopulations.
- [0042] Figure 21B. Figure 21B shows FOV activation and synchronization of calcium transient cycles by 1.0 Hz field stimulation in d6 myotubes.
- [0043] Figure 21C. Figure 21C shows FOV calcium transient activation of d6 myotubes by 10 mM caffeine.
- [0044] Figure 21D. Figures 21D: single-cell analysis of calcium transient activation in a d7 myotubes by 100 nM acetylcholine.

DETAILED DESCRIPTION

- [0045] To the extent necessary to provide descriptive support, the subject matter and/or text of the appended claims is incorporated herein by reference in their entirety. It will be understood by all readers of this written description that the exemplary embodiments described and claimed herein may be suitably practiced in the absence of any recited feature, element or step that is, or is not, specifically disclosed herein.
- [0046] Throughout this disclosure, the term "a" or "an" entity refers to one or more of that entity; for example, "a polynucleotide," is understood to represent one or more polynucleotides. As such, the terms "a" (or "an"), "one or more," and "at least one" can be used interchangeably herein.
- [0047] Furthermore, "and/or" where used herein is to be taken as specific disclosure of each of the two specified features or components with or without the other. Thus, the term "and/or" as used in a phrase such as "A and/or B" herein is intended to include "A and B," "A or B," "A" (alone), and "B" (alone). Likewise, the term "and/or" as used in a phrase such as "A, B, and/or C" is intended to encompass each of the following aspects: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).
- [0048] It is understood that wherever aspects are described herein with the language "comprising," otherwise analogous aspects described in terms of "consisting of" and/or "consisting essentially of" are also provided.
- [0049] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to whom this disclosure is directed. For example, the Concise Dictionary of Biomedicine and Molecular Biology, Juo, Pei-Show, 2nd ed., 2002, CRC Press; The Dictionary of Cell and Molecular Biology, 3rd ed., 1999, Academic Press; and the Oxford Dictionary Of Biochemistry And Molecular Biology, Revised, 2000, Oxford University Press, provide one of skill with a general dictionary of many of the terms used in this disclosure .
- [0050] Units, prefixes, and symbols are denoted in their Système International de Unites (SI) accepted form. Numeric ranges are inclusive of the numbers defining the range. Unless otherwise indicated, nucleic acid sequences are written 5' to 3' and amino acid sequences are written left to right in amino to carboxy orientation. The headings provided

herein are not limitations of the various aspects of the disclosure, which can be had by reference to the specification as a whole.

- [0051] All methods described herein can be performed in any suitable order unless otherwise indicated herein.
- [0052] No language or terminology in this specification should be construed as indicating any non-claimed element as essential or critical.
- [0053] Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. Where a specific range of values is provided, it is understood that each intervening value is intended to be included therein, and all smaller subranges are also included.
- [0054] Provided herein are new and improved methods for generating functional skeletal muscle, for cultivating meat such as engineered tissue or other comestible product, from a cell source *in vitro*. Such methods are contemplated, for example, for livestock-autonomous meat production, wherein meat is any metazoan tissue or cell-derived comestible product intended for use as a comestible food or nutritional component by humans, companion animals, domesticated or captive animals whose carcasses are intended for comestible use, service animals, conserved animal species, animals used for experimental purposes, or cell cultures.
- [0055] Also provided are *in vitro*-produced animal tissues, such as muscle tissue, made by any of the various aspects disclosed herein. In certain aspects, the cell source is a stem cell source, for example, a self-renewable stem cell line. Certain aspect of the methods employ a myogenic, inducible transgene-modified self-renewable cell line derived from an intended species. In certain aspects, the intended species can be any edible species including livestock and poultry species. In certain aspects, the intended species are livestock species such as domestic cattle, pigs, sheep, goats, camels, water buffalo, rabbits and the like. In certain aspects, the intended species are poultry species such as domestic chicken, turkeys, ducks, geese, pigeons and the like. In certain aspects, the intended species are common game species such as wild deer, gallinaceous fowl, waterfowl, hare and the like. In certain aspects, the intended species are aquatic species or semi-aquatic species harvested commercially from wild fisheries or aquaculture operations, or for

sport, including certain fish, crustaceans, mollusks, cephalopods, cetaceans, crocodilians, turtles, frogs and the like. In certain aspects, the intended species are exotic, conserved or extinct animal species. In certain aspects, the intended species are any metazoan species demonstrating the capacity for skeletal muscle tissue specification. In certain aspects, the intended species are for research or for therapeutic purposes, such as humans, primates, rodents including rats and mice, and companion animals such as dogs, cats, horses, and the like.

[0056] In certain aspects, the cell line is regulated by a double-switch mechanism to either maintain the cell line in self-renewal process or direct myogenic differentiation.

[0057] A parent/host cell line of aspects disclosed herein has the properties of being immortal (self-renewing) and having the potential to differentiate, reprogram, specify or otherwise convert to skeletal muscle lineage, such as following regimens comprising one or more components that direct myogenic conversion. Three classes of stem cell may be employed as cell sources for scalable cultivation: (1) lineage-restricted primary adult progenitor stem cell isolations, (2) lineage-restricted immortalized cell lines, and (3) pluripotent stem cells lines. It has been determined that each of these approaches has advantages and disadvantages in serving as a cell source for cultured meat production.

Lineage-Restricted Primary Adult Progenitor Stem Cell Isolations. These include adult progenitor cells committed to lineages constituting meat products such as skeletal muscle. Skeletal muscle progenitor cells include, but are not limited, to satellite cells, myoblasts and myocytes. Their advantages include: i) primary adult progenitor cells are restricted to specific lineages and require little or no *in vitro* specification to desired lineages; and ii) primary adult progenitor cells do not require genetic modification for lineage specification. Their disadvantages include: i) they must either be harvested from a freshly slaughtered animal carcass or procured from an invasive biopsy. Either method conveys dependence on livestock and compromises the benefit of livestock-autonomous production to the extent that livestock are used in the process; ii) primary cell isolation is a highly inefficient process. The desired cells comprise a fraction of the source tissue. A subfraction of the desired cells survive the isolation process. Desired cell lineages must be isolated from mixed populations of surviving cells, requiring additional purification and expansion steps; iii) primary adult progenitor cells are subject to the 'Hayflick Limit', wherein cells can divide only limited number of times before they

lose their capacity to proliferate. Moreover, primary adult progenitor cells lose their ability to terminally differentiate in a manner concordant with extended passage. Thus, additional cells must be procured from primary cell isolations, thereby limiting cultivation scalability from a single isolation; and iv) primary cell culture of lineages of tissues applicable to cultured meat production, such as skeletal muscle, are anchorage dependent-limiting methods for volumetric scalability of cultures. In suspension culture, these cells may be susceptible to cell death by anoikis.

[0058] Lineage-Restricted Immortalized Cell Lines. These are lineage-committed primary cells that are genetically altered to self-renew indefinitely while retaining their capacity to terminally differentiate or lineage-restricted. Their advantages include: i) “perpetually self-renewing” (i.e. not subject to the ‘Hayflick Limit’) and can expand indefinitely for scalable and livestock-autonomous cultivation; ii) restricted to specific lineages and require little or no further *in vitro* specification. Their disadvantages include: i) immortalized, lineage-restricted cell lines from certain species with the capacity to differentiate along lineages applicable to cultured meat production (e.g. skeletal muscle) may require development; ii) cultures of lineage-committed cell lines are anchorage dependent, limiting scalability. In suspension culture, lineage-committed cell lines may be susceptible to cell death by anoikis; and iii) cellular transformation(s) enabling ‘immortalization’ necessitates genetic modification. The necessary genetic modifications that immortalize applicable primary cell populations without interfering with their capacity to terminally differentiate are not well characterized.

[0059] Pluripotent Stem Cells Lines: Pluripotent stem cell lines include embryonic stem cells or induced pluripotent stem cells (iPSC) that maintain the capacity to self-renew in the undifferentiated state, or alternately differentiate to any tissue lineage. Their advantages include: i) in general, pluripotent stem cell lines proliferate at a higher rate than primary or immortalized lineage-restricted cell lines, reducing the time required for biomass expansion in production processes; ii) pluripotent stem cells may be cultivated as embryoid bodies in suspension culture, thereby enhancing culture scalability per unit of culture volume. Moreover, embryoid bodies may be cultured as ‘bio-ink’ compatible with micromold and bioprinting tissue assembly methods; and iii) like immortalized lineage-restricted cell lines, pluripotent stem cells are not subject to the ‘Hayflick Limit’ and can expand indefinitely for scalable, livestock-autonomous cultivation. Their disadvantages

include: i) authentic embryonic stem cell lines derived from certain species may require development; ii) methods for reprogramming and self-renewal of iPSC may be transgene-dependent. Hence, iPSC pluripotency may require genetic modification for induction and self-renewal of the undifferentiated state. Efficient iPSC differentiation requires mechanisms for silencing the transgenes used for reprogramming and maintenance of the undifferentiated state mutually exclusive to the differentiated state to avoid conflicting transcription network activation disadvantageous to desired lineage specification; and iii) relative to lineage-restricted primary adult progenitor stem cells and immortalized cell lines, pluripotent stem cells, in general, require additional lineage specification steps to develop and enrich the desired lineage specification.

[0060] Other parental/host cells lines in addition to the three stem cell classifications provided above are also contemplated herein. For example, induced trophoblast cell lines (representing non-pluripotent, non-somatic immortalized cells of extra-embryonic type), whose myogenic potential was established previously by the teratoma assay, may be suitable for myogenic conversion as well. For example, somatic cell lines partially reprogrammed to pluripotency may possess myogenic potential but fail to form teratomas representing three embryonic germ layers. For example, though their existence is controversial, STAP cell lines (stimulus-triggered acquisition of pluripotency) may be myo-potent and self-renewing.

[0061] **O2K cell line.** The O2K cell line is an induced pluripotent stem cell line established from the inner cell mass of a pre-implantation porcine embryo. The O2K cell line has been studied and it was discovered that the self-renewal state of O2K can be maintained by transcriptional activation of *POU5F1* and *KLF4* transgenes by doxycycline (i.e. DOX) using a 'Tet-On' induction system.

[0062] **MYOD1 transcription factor.** MYOD1 (i.e. MyoD) is a dominant regulator of skeletal muscle lineage commitment. The MyoDER construct has been described previously, consisting of a genetic fusion of the murine *MYOD1* gene and the sequence encoding the ligand binding domain of the human estrogen receptor α , shown in Figure 1 (SEQ ID NO: 1). In Figure 1, the MyoDER consists of a genetic fusion between the murine MYOD1 gene at the *Nar* I restriction endonuclease digest site with the ligand binding domain coding sequence of the *ESR1* (i.e. human estrogen receptor α) nucleotides 844-1781. Non-specified and *Cla* I linker sequences are also present. The myogenic

specification activity of the MyoDER fusion construct is post-translationally induced by addition of the estrogen receptor α ligand, 17 β -Estradiol (i.e., E2). In the absence of the 17 β -estradiol, MyoDER remains in an inactive state. The MyoDER construct is herein referred to as “inducible MyoD.”

[0063] Referring now to Figure 2, one aspect is cell-stock-expansion, i.e., expansion of the cell line in self-renewal conditions necessary for the maintenance of cell stocks for continued scalable cultivation. Another aspect is the lineage-specification/differentiation, i.e., inducing myogenic lineage differentiation for further tissue cultivation process. Thus, certain aspects may be summarized as comprising two main steps: i) modifying a selected self-renewing cell line with a myogenic transcription factor to produce an myogenic-transcription-factor-modified cell line, and ii) inducing such modified cell line by exogenous regulation to maintain in self-renewal process or advance to differentiation process. As used herein, “modifying” a cell line with an myogenic transcription factor refers to inserting a nucleic acid vector or construct operably encoding a myogenic transcription factor (such as by transfection, transduction, transformation, and the like) into the cell line, wherein the modified cell line expresses the myogenic transcription factor. In certain aspects, the inserted myogenic transcription factor is inducibly-expressed to produce an inducible-myogenic transcription factor cell modified cell line. As used herein, “inducibly,” “inducible,” and the like refers to any genetically engineered approaches that may be used to exogenously regulate the activities of a gene product such as a myogenic transcription factor. Inducible approaches include, but are not limited to, regulation of myogenic transcription factor activity by ligand inducible transcription factor technology (e.g., tet-on, tet-off, RheoSwitch), site-directed recombination technology (e.g., Cre-LoxP, flp-FRT), transposon technology (e.g. Sleeping Beauty, PiggyBac), ligand binding receptor fusion technology (e.g., estrogen, progesterone, androgen, thyroid hormone, glucocorticoid hormone, tamoxifen ligand agonists), and transient transfection of extrachromosomal expression vectors bearing a myogenic transcription factor gene. In certain aspects, the nucleic acid construct or vector is chromosomally integrated into the modified cell line. Representative examples of self-renewing cell lines include those selected from a group consisting of embryonic stem cells, induced pluripotent stem cells, and immortal lineage-restricted cell lines. In certain aspects, such self-renewing cell lines are derived from species intended for dietary

consumption or for research or for therapeutic purposes. Representative examples of myogenic transcription factors include, used alone or in combination, MYOD1, MYOG, MYF5, MYF6, PAX3, PAX7, paralogs, orthologs, genetic variants thereof, or transcriptional activation agonists of the respective promoter recognition DNA sequences of the myogenic transcription factors disclosed herein.

[0064] Reference is made now to Figure 3, which includes exemplary schematic illustrations of the double-switch mechanism of the myogenic modified O2KM cell line regulated by DOX or E2. As shown in Figure 3, during the O2KM stem cell self-renewal process, the expression of the pluripotency transgenes *POU5F1* and *KLF4* is induced in the presence of DOX in the self-renewal medium (SRM), while such expression is repressed when DOX is absent. Similarly, during the O2KM myogenic differentiation process, myogenic differentiation is activated by the inducible MyoD transgene in the presence of E2 in the myogenic induction medium (MIM), while such directed differentiation is inactive when E2 is absent.

[0065] Certain aspects provide differentiation/specification methods comprising additional reagents other than E2 in the MIM to prevent cell death and to modulate the epigenetic state of chromatin. For example, a Glycogen Synthase Kinase-3 β (GSK3 β) inhibitor can be added to the SRM and MIM to activate the canonical WNT signaling pathway, in turn, enhance myogenic differentiation and reduce cell death at the time of DOX withdrawal. Without being limited by theory, in certain aspects, the epigenetic modular alters the chromatin activation by myogenic transcription factors and/or enhances expression of myogenic transcription factors, such as MYF5.

[0066] It is understood that GSK3 β inhibition includes targeting with small-molecules. Gene editing is also a promising approach to enhance skeletal muscle specification by WNT signaling activation. For example, GSK3 β may be inhibited in the host/parental cell line by mutating the GSK3 β alleles either by sequence-specific insertion or deletion technology (i.e. Zinc-Finger Nuclease, TALEN, CRISPR). Mutating the endogenous promotor region can be used to repress expression of GSK3 β . Alternately, the GSK3 β open reading frame may be deleted or mutated using the same methods to abolish GSK3 β activity. Likewise, the downstream phosphorylation target of GSK3 β , beta-catenin (CTNNB1) may be mutated at the codons coding for residues phosphorylated by GSK3 β , thereby preventing phosphorylation of CTNNB1 by GSK3 β , resulting in a constitutively

active, stable CTNNB1. Such “gene-editing” methods would reduce the cost of GSK3 β inhibition by small-molecule targeting and potentially improve the safety profile of the meat product, as additional chemicals would not be required to inhibit GSK3 β during the process. It is contemplated that a third approach to Wnt-signaling inhibition includes the use of anti-sense nucleic acid inhibitors to GSK3 β or other factors antagonistic to the WNT pathway. These may include RNA interference methods using sequence-targeting shRNA or miRNA.

[0067] Certain specific aspects provide for use of a GSK3 β inhibitor to promote cell survival, for example at the time of DOX withdrawal. One illustrative example of a GSK3 β inhibitor is CHIR99021. Additional representative GSK3 β inhibitors may include, without limitation: lithium chloride, BIO, SB216763, CHIR-98014, TWS119, Tideglusib, IM-12, 1-Azakenpullone, AR-A014418, and SB415286. Without being bound by theory, it is believed that concomitant with DOX, both self-renewal of undifferentiated cells is maintained by a WNT signaling pathway involving the inhibition of GSK3 β .

[0068] Without being bound by theory or limited by any specific representative example, it was observed that simultaneous withdrawal of both DOX and the GSK3 β inhibitor CHIR99021 from the culture medium supplemented with N-2 and B-27 serum replacements precipitates massive cell death of differentiating O2K parental line within 48h hours. Withdrawal of DOX in the presence of CHIR99021 enabled survival of the differentiating O2K. Death by differentiating O2K cells in the absence of a GSK3 β inhibitor and reciprocal survival in the presence thereof was confirmed by morphology, cell adhesion assay, cleaved caspase-3 accumulation, and Annexin V labeling. In the parental O2K cell line, inhibition of GSK3 β concordantly resulted in the stabilization and activation of its phosphorylation substrate, CTNNB1, the downstream positive effector of the canonical WNT signaling pathway. WNT signaling plays crucial roles in both mesoderm specification from the undifferentiated ground-state pluripotency, pre-myogenic enrichment from unpatterned mesoderm and terminal differentiation of committed myocytes both *in vivo* and *in vitro*. In agreement, extended culture of the O2K line in the absence of DOX, and in the presence of a GSK3 β inhibitor, supported differentiation toward the pre-myogenic paraxial mesoderm, as evidenced by the expression of PAX3 and concomitant loss of POU5F1 and KLF4 expression.

Furthermore, in combination with 5AC, the GSK3 β inhibitor enhanced expression of the myogenic transcription factor MYF5 in differentiating O2K. Moreover, a GSK3 β inhibitor, such as CHIR99021, enhanced the terminal differentiation of the myogenic murine C2C12 cell line into multi-nucleated myotubes, as shown in Table 1.

[0069] Table 1 lists the influences of extracellular matrix effectors (i.e. Gelatin, Poly-D-Lysine, Laminin, MATRIGEL) and soluble factors (E2, CHIR99021) on the terminal differentiation of the murine C2C12 myoblast by assessment of the size and extent of myotube formation proceeding a 5-day differentiation time course. (Cultures were scored from [*****], indicating robust myotube formation to [-] indicating non-detectable myotube formation.)

Table 1. Influence of Extracellular Matrix effectors and Soluble factors on the terminal differentiation.

	Basal Medium	+5 μ M E2	+3 μ M CHIR	+5 μ M E2, +3 μ M CHIR
Gelatin	***	**	***	**
Gelatin + Poly-D Lysine	***	*	*	-
Laminin + MATRIGEL + Poly-D Lysine	***	*	**	**
Laminin + MATRIGEL	***	*	*****	**
Laminin	***	*	***	*
MATRIGEL	***	**	*****	***

[0070] In certain aspects due to its multifunction: (1) suppressing cell death following DOX withdraw, (2) supporting differentiation toward the pre-myogenic state, (3) enhancing myogenic specification, and (4) enhancing terminal differentiation, a GSK3 β inhibitor when retained in the culture medium during differentiation (in the absence of DOX), is deemed compatible with the inducible myogenic transcription factor directed lineage specification and subsequent terminal differentiation conditions by derivative myocytes. For example, CHIR99021 was retained in the O2KM cultures following DOX

withdrawal during subsequent E2-induced lineage-specification and terminal differentiation processes.

[0071] However, though the aforementioned GSK3 β inhibitor-supplemented culture regimen supported cell survival and myogenic lineage specification by O2KM to differentiated cells with distinctive myocyte-like spindle morphology, the derivative cells failed to terminally differentiate into refractive elongated myotubes. Therefore, an epigenetic modulator was used to enhance the expression of myogenic genes in cells otherwise non-permissive to myogenesis and enhance terminal differentiation of lineage committed myocytes to mature myofibers. To enable terminal differentiation of O2KM, cells were cultured in the presence of 5-Aza-Cytidine (5AC) for 72 hours preceding DOX withdrawal, for 48 hours during E2 induction, followed by a terminal differentiation period up to 6 additional days. In O2KM derived myocytes cultured in the presence of 5AC, MYF5 expression was enhanced and cells exhibited a refractive myofibril morphology, whereas myocytes derived in the absence of 5AC expressed reduced MYF5 and exhibited a flattened morphology atypical to mature myofibrils. This distinction may be explained by the enhanced expression of the myogenic transcription factor MYF5 observed only in the 5AC-exposed O2KM prior to and following 48 hours of DOX withdrawal.

[0072] In conjunction with enrichment of the lower molecular weight, non-phosphorylated myogenin isoform, known to be the active transactivator, the morphological distinction among these cultures may be explained by MYF5 expression enhanced by 5AC exposure. It is understood that epigenetic modulation entails alteration of chromatin structure influencing transcription factor binding and targeted transcriptional activation by altering the DNA methylation patterns and post-translational modification of nucleosome-associated histones. It is understood that epigenetic modulation may entail small-molecule agonists or antagonists targeting epigenetic pathways or expressed proteins comprising epigenetic machinery. One illustrative example of a small-molecule epigenetic modulator is 5-Aza-Cytidine (5AC). Additional representative examples of small molecule epigenetic modulators include 5-Aza-2'-deoxycytidine, RG108, Scriptaid, sodium butyrate, trichostatin A, Suberoylanilide Hydroxamic Acid, MS-275, CI-994, BML-210, M344, MGCD0103, PXD101, LBH-589, Tubastatin A, NSC3825, NCH-51, NSC-3852, HNHA, BML-281, CBHA, Salermide, Pimelic Diphenylamide, ITF-2357,

PCI-24781, APHA Compound 8, Droxinostat, and SB-939. Representative examples of proteins involved in epigenetic modulation include histone deacetylase paralogs, histone acetyltransferase paralogs, tet-methylcytosine dioxygenase paralogs, histone demethylase paralogs, histone methyltransferase paralogs, and DNA methyltransferase paralogs, histones, and subunits of chromatin remodeling complexes including Mi-2/NuRD (and its components such as methyl-CpG-binding domain protein 3 (MBD2)) and SWI/SNF (and its components such as BAF60 and BAF60C). It is further understood that respective activities of protein epigenetic modulators may be influenced by representative modalities such as targeting by small-molecule factors, over-expression of a respective exogenous transcript, anti-sense RNA-targeted respective transcript degradation, RNAi, and targeted mutation at the genetic locus.

[0073] The following disclosed embodiments are merely representative. Thus, specific structural, functional, and procedural details disclosed in the following examples are not to be interpreted as limiting.

EXAMPLES

Methods

[0074] **O2KM cell line.** The O2KM cell line was derived from the parental O2K cell line by lentiviral insertion of a blasticidin-selectable transgene cassette containing the MyoDER open reading frame sequence (ORF). As referred to in this example section, O2K cells/cell line and piPSC cells are used interchangeably. The lentiviral vector, illustrated in Figure 4A, was prepared by cloning the MyoDER ORF (Addgene #13494) downstream of the CMV promoter of the pLentiCMVBlast destination vector (Addgene #17451) between the attR1 and attR2 recombination sites from an pENTR/D-TOPO entry vector (Life Technologies #K2435-20) clone containing the PCR-amplified MyoDER ORF. To prepare the lentiviral supernatant, 293FT cells were co-transfected with the prepared pLentiCMVBlast[MyoDER] plasmid, the pMD2.G envelope plasmid (Addgene #12259) and the psPAX2 packaging plasmid (Addgene #12260) using the PolyJet transfection reagent (Signagen # SL100688). O2K was transduced with pseudovirus concentrated from the 293FT supernatant. Transduced O2K were cultured in phenol-red free culture medium and selected four days with 10 µg/mL blasticidin followed by two

additional days with 15 $\mu\text{g/mL}$ blasticidin. Selected cells were designated as O2KM. Expression of MyoDER in the O2KM stock was verified by Western blot, Figure 4B

[0075] *O2KM stem cell stock expansion in presence of DOX.* O2KM stem cell renewal milieu was conducted as for the parental O2K line, with the following exception: phenol-red free formulations of DMEM/F-12 and neurobasal medium were substituted for the phenol-red containing formulations to avert pleotropic agonistic effects on MyoDER (i.e. activation). The O2KM cell stock self-renewal medium (SRM) consisted of the following components: phenol-red-free neurobasal medium (Life Technologies #12348-017), phenol-red free DMEM-F12 (Life Technologies #11039-021), 1X non-essential amino acids (Sigma-Aldrich #M7145), 0.5X Glutamax (Life Technologies #35050061), 0.000007% β -Mercaptoethanol, 0.5X N2 Supplement (Life Technologies #17502048), 0.5X B27 Supplement Minus Vitamin A (Life Technologies #12587010), 0.1 mg/mL Bovine Serum Albumin, 2 $\mu\text{g/mL}$ doxacycline hyclate (i.e. DOX), 10 ng/mL human leukemia inhibitory factor (hLIF, Millipore #LIF1050), 3 μM CHIR99021, 0.8 μM PD032591 and 0.1 μM PD173074. Herein forth, the three inhibitors CHIR99021, PD032591 and PD173074 are collectively regarded as '3i'. Alternatively, N-2 and B-27 serum replacements were substituted using 15% KnockOut Serum Replacement (KOSR; Life Technologies #A15870). O2KM maintained by enzymatic dissociation of colonies and passages of cells onto culture dishes coated with poly-D lysine and murine laminin in phenol-free SRM under 5% O_2 every 3d. In these self-renewal conditions, O2KM maintained compact, stem cell-like morphology as the parental O2K line, as shown in Figure 5.

[0076] *CHIR99021 inhibition of cell death.* Differentiation of the parental O2K line in the absence of SRM culture medium components that support self-renewal hLIF, DOX, CHIR99021, PD032591 and PD173074, and KOSR resulted in massive cell death as determined by (1) phase contrast microscopy as shown in Figure 9, panels i. – ii., (2) CPP32 cleavage, as shown in Figure 17A, and (3) Annexin V labeling shown in Figure 16. However, a culture medium formulation including CHIR99021, when retained in the SRM basal medium in the absence of hLIF, DOX, PD032591 and PD173074, supported both cell survival during differentiation as determined by (1) phase-contrast microscopy, as shown in Figure 9, panels iii. – viii., (2) cell adhesion assay, as shown in Figure 10, (3) CPP32 cleavage inhibition as shown in Figure 17B, and (4) Annexin V labeling, as shown

in Figure 11. Moreover, CHIR99021 exposure during primordial differentiation stabilizes and modulates the phosphorylation status of the GSK3 β substrate, CTNNB1, as shown in Figure 12, 13A and 13B, the phospho-regulated downstream effector of the canonical WNT signaling pathway known to direct mesodermal differentiation during embryonic lineage specification, myogenic enrichment of mesodermal progenitors, and terminal differentiation of skeletal myocytes. Congruent with these findings, CHIR99021 supplemented basal medium supported pre-myogenic paraxial mesoderm lineage specification of differentiating O2K, as shown in Figure 14 and when included in low-mitogen differentiation cultures (2% horse serum/DMEM) of the myogenic murine C2C12 cell line, enhanced terminal differentiation into skeletal myotubes, listed in Table 1. As CHIR99021 repressed cell death, supported differentiation toward paraxial mesoderm by the differentiating O2K cell line and enhanced terminal differentiation by the C2C12 cell line, precedent was established to retain the compound in all culture stages. Hence, 3 μ M CHIR99021 was retained in the culture medium during expansion, induction and terminal differentiation steps (Figure 20A) unless stated otherwise.

[0077] ***O2KM myogenic induction.*** O2KM cells were seeded onto culture dishes coated with poly-D lysine, murine laminin and MATRIGEL at a density of 4.1×10^3 cells/cm² and cultured under 5% O₂ in self-renewal medium for 3d. To facilitate differentiation, cultures were transferred to a 20% O₂ basal differentiation milieu, designated by withdrawal of PD032591, PD173074, DOX, hLIF and β -mercaptoethanol. To conditionally induce the expressed MyoDER protein, 10 μ M E2 was added to the medium. E2-directed myogenic lineage specification following 2d induction culture was confirmed by (1) adoption of spindle-like morphology characteristic of skeletal myocytes in treated cultures, as shown in Figure 6, (2) expression of endogenous the MYOG skeletal muscle transcription factor, as shown in Figure 7 and (3) uniform expression of the skeletal myocyte cell surface marker, NCAM, as shown in Figure 8.

[0078] ***5AC effects.*** 5AC exposure prior to, during, and following E2-mediated induction of 'MyoDER' was introduced to enable terminal-differentiation of O2KM from myocytes into refractive, filamentous myotubes. The murine C2C12 cell line was used as positive control to screen for optimal conditions for terminal differentiation by O2KM. These conditions included: a MATRIGEL extracellular matrix and CHIR99021 supplementation in the absence of E2, as listed in Table 1. However, O2KM-derived myocytes passaged

onto MATRIGEL-coated culture dishes in differentiation medium without E2 (the conditions determined optimal for C2C12 terminal differentiation) failed to establish refractive myotubes, as shown in Figure 15 and Figure 20B. Hence, the gene expression program in the O2KM-derived myocytes was not sufficient to enable terminal differentiation as per the established conditions. 5AC, a small-molecule epigenetic modulator, was determined previously to enable skeletal muscle transcription in cell lines non-permissive to myogenesis. Moreover, 5AC exposure was further determined to enhance terminal differentiation by the C2C12 cell line. Hence, 250 nM 5AC, the highest dose tolerated by undifferentiated O2KM, was included during in the proliferative O2KM expansion and induction regimens, as shown in Figure 20A.

[0079] **Terminal Differentiation.** Following 2d E2 induction, cultures were either terminally differentiated *in situ*, or passaged to MATRIGEL-coated culture dish in terminal differentiation medium (TDM) at 1.56×10^5 cells/cm² for terminal differentiation. TDM was formulated from the same components as MIM, except for the following modifications: withdrawal of E2, addition of 4 μ M A 83-01, and 100 nM IGF-1. N-2 and B-27 supplements were used exclusively as serum replacements. Cultures were differentiated for up to 6d following under 20% O₂ following induction regimens (Figure 20A). Cultures exposed to 5AC during expansion and induction regimens formed refractive, anisotropic myotubes during the terminal differentiation regimen, shown in Figure 20B. Figure 20C shows uniform expression of myosin heavy chain by d6, and Figure 20E shows increasing expression of desmin (DES) and myogenin (MYOG) over the 8d course. Myotube polyploidy was observed during terminal differentiation, as shown in Figure 20D, left panel. The relative distribution of myonuclei in d8 myotubes according to ploidy is shown in Figure 20D, right panel. Relative prevalence of S-phase nuclei in the renewal milieu (d3 colonies), expansion milieu (d0 cultures, Figure 20A), and terminal differentiation milieu (d8 cultures, Figure 20A), as shown in Figure 20F, indicated cell cycle withdrawal following terminal differentiation. Contractile potential of terminally differentiating skeletal muscle myotubes was validated by (1) structural development of well-organized sarcomeres, as shown in Figure 20G; (2) asynchronous spontaneous contraction, as shown in Figure 21A; (3) contractile stimulation and synchronization by field stimulation, as shown in Figure 21B; (4) caffeine-stimulated

contraction, as shown in Figure 21C; and (5) acetylcholine-stimulated contraction, as shown in Figure 21D.

Results

[0080] An axis of apoptosis and differentiation is modulated by CHIR99021. Figure 9 shows phase-contrast images of ground-state piPSC colonies cultured under 5% O₂ in the self-renewal milieu (i.) and following 48h under 20% O₂ in the absence of DOX, LIF and 3i, (ii.). Figure 16 shows Annexin V labeling of apoptotic cells prior to, and following 24h transition of cultures. Figure 17A shows Western blot detection of full-length CPP32 (~32 kD procaspase 3a) and the large cleaved fragment (~17kD cleaved-caspase 3a) in ground-state colonies prior to (0h) and following (12-48h) differentiation milieu transition (12-48h). Figure 9 shows phase contrast images of adherent cultures (iii, iv, vi, and vi) and non-adherent embryoid body cultures (vii and viii) following 48h culture in differentiation milieu supplemented with CHIR99021 as indicated. Figure 10 shows adherent cell percentage of differentiation milieu cultures supplemented with the CHIR99021 as indicated for 48h relative to ground-state (i.e. 0h) cultures, normalized to 100%. *non-adherent cells viable as embryoid bodies. *n* = 3 for each culture condition. Figure 11 shows Annexin V labeling of apoptotic cells following 24h transition of cultures to differentiation milieu supplemented with CHIR99021 as indicated. Figure 17B shows Western blot detection of full-length CPP32 and the cleaved fragment in colonies following 42h transition to the differentiation milieu in the presence of CHIR99021 levels indicated. TUBA is detected an internal protein loading control.

[0081] CHIR99021 stabilizes CTNNB1 and supports differentiation from the ground state. Figure 12 shows Western blot detection of CTNNB1 and p-CTNNB1 (total and phospho-S33,37,T41 β -catenin, respectively) following 24h differentiation milieu transition in the presence of CHIR99021, as indicated. TUBA detected as an internal protein loading control. Figure 13A indicates ratios of p-CTNNB1/CTNNB1 bands. Figure 13B indicates ratios of CTNNB1/TUBA bands. Figures 13A and 13B represent densitometric quantitation from Western Blots as shown in Figure 12; *n* = 3. Figure 18 shows outgrowth morphology of embryoid bodies formed in a differentiation milieu containing 6 μ M CHIR99021 for two days and following transfer to a Poly-D Lysine + Laminin + MATRIGEL coated substrate for one (d3, *left panel*) or three (d5, *right panel*)

additional days. Figure 14 shows Western blot analysis of PAX3, POU5F1 and KLF4 expression in ground-state milieu (d0) and differentiation milieu cultures (d1 – d5) according to one regimen aspect described elsewhere herein. TUBA detection is shown as an internal protein loading control.

[0082] 5-Aza-cytidine and MyoDER activation of endogenous MRFs. piPSC modification with an integrated MyoDER expression cassette. Figure 4A shows a Blasticidin (BLAST)-selectable MyoDER expression cassette. Arrows and boxes indicate promoter and gene sequences, respectively. Figure 4B shows Western blot detection of MyoDER in the unmodified (O2K) and MyoDER expression cassette-modified (O2KM) piPSC line. MyoDER was detected with an antibody raised against a MyoD peptide. Figure 7 shows Western blot detection of MyoDER (~75 kD), MYF5 and MYOG following 2d piPSC induction. Endogenous MYOD1 (~45 kD, expected) was not detected. O2KM were seeded onto poly-D lysine + Matrigel + murine laminin coated culture dishes and cultured with hLIF, 3i & DOX for three days in the presence (i.e. expansion, Figure 20A) or absence of 5AC, followed by respective transition to a +/- 5AC differentiation milieu supplemented with E2 (i.e. 17 β estradiol) and 3 μ M CHIR99021 for two days. *Double Arrow*: Partially resolved MYOG isoforms. Figure 19A and 19B. Determinants of MYF5 activation: Western blot analyses. Figure 19A, following three days of culture on poly-d-lysine + laminin + MATRIGEL, unmodified piPSC were cultured 2d in the absence of 3i, DOX, hLIF and E2 in differentiation milieu supplemented with 5AC (as in Figure 7) and CHIR99021 as indicated. In the absence of CHIR99021, the 17 kD cleaved caspase isoform was not observed in the KOSR supplemented differentiation milieu, as in contrast to observations in the N-2 and B-27 supplemented differentiation milieu (Figure 17A, Figure 19A). 5AC-enhanced activation of endogenous MYF5 expression was dependent upon simultaneous CHIR99021 exposure, as shown in FIG. 19A. Figure 19B shows MYF5 activation in the presence of DOX, LIF and 3i. MYODER-modified piPSC were cultured 3 days in self-renewal or expansion milieu. In the presence of DOX and CHIR99021, 5AC exposure supported detectable MYF5 expression levels, as shown in Figure 19B, after 3 days of expansion culture. In contrast MYF5 was not detected following 3 days of renewal culture (-5AC), as shown in Figure 19B. TUBA is detected as an internal protein loading control. Figure 6 shows the morphology of selected piPSC cultures following lineage specification

induction culture regimens (Figure 20A) described elsewhere herein. Figure 8 shows immunocytofluorescent detection of nuclei (DAPI) and NCAM in piPSC-MyoDER cultures prior to (d0, *left panel*) and following (d2, *right panel*) 10 μ M E2 exposure, in the presence of 5AC.

[0083] **Terminal Myogenesis of Lineage-Specified piPSC.** Prior to terminal differentiation, cultures were expanded for 3 days in the presence of 5AC, induced for 2 days in the presence of E2 & 5AC, and terminally differentiated in the absence of 5AC & E2 as shown in Figure 20A. Figure 20B shows myotube morphology and conformation. Post-induction (d2), piPSC developed as elongated, anisotropic, refractive myotubes. Where 5AC was not included in the expansion and induction steps, cells exhibited a flattened, non-refractive morphology. Figure 20C and Figure 20E show terminal myogenesis protein expression. D0 and D6 cultures were stained for myosin heavy chain (MyHC) isoforms with a pan-MyHC monoclonal antibody, clone MF20. Figure 20D shows myotube multinucleation. *Left panel*: enlarged image of d4 terminal differentiation cultures. Bracketed arrows indicate multiple nuclei within a single myotube. *Right panel*: myonuclei distribution by myotube ploidy by propidium iodide labeling and flow cytometry analysis. $n = 3$ with standard deviation shown. Figure 20E shows Western blot analyses. MyoD (MYOD1), myogenin (MYOG) and desmin (DES) expression, d0 –d8. TUBA is detected as an internal protein loading control. Figure 20F shows cell-cycle withdrawal coinciding with terminal differentiation. d3 modified piPSC renewal, expansion cultures and d8 terminal differentiation cultures were labeled with EdU, and the S-phase fraction was determined by flow cytometry. $n = 3$ with standard deviation shown. Figure 20G: Transmission Electron Microscopy, d6 myotubes. Sarcomeric structural units were aligned in single (*left panels*) and staggered, parallel rows (*right panel*).

[0084] **Spontaneous and Stimuli-Induced Calcium Transient Activity in piPSC-derived myotubes.** To quantify contraction cycles, myotube cultures were stained with Fluo-4 AM calcium dye, washed, and image sequences were captured by confocal microscopy. Dynamic signaling events of an entire field of view (FOV) or single cells were traced and plotted over the imaging course. [s] = seconds. Figure 21A shows representative asynchronous, single-cell transient cycles (*left, middle and right panels*) were observed in spontaneously contracting d6 myotube subpopulations. Figure 21B

- 25 -

shows FOV activation and synchronization of calcium transient cycles by 1.0 Hz field stimulation in d6 myotubes. Figure 21C shows FOV calcium transient activation of d6 myotubes by 10 mM caffeine. Figures 21D: single-cell analysis of representative calcium transient activation in a d7 myotubes by 100 nM acetylcholine.

Discussion

[0085] In summary, it has been discovered that certain aspects of the exemplary embodiments described in this disclosure demonstrate one or more of the following unexpected advantages for cultured meat applications:

- (i) Rapid Cell Proliferation Rate;
- (ii) Rapid Differentiation: With as little as 48 hours of 17 β -estradiol induced MyoDER activation and doxycycline withdrawal, the O2KM cell line differentiates to the myogenic lineage, in vitro. No lengthy differentiation procedures required;
- (iii) Efficient Differentiation: The CHIR99021/5AC/MyoDER-directed lineage specification ensures extensive high-fidelity conversion to functional skeletal myocytes. No cell sorting is required;
- (iv) Infinite Self-Renewal: Self-renewal of undifferentiated O2KM is tightly enforced supported in the self-renewal milieu;
- (v) Self-Renewal and Terminal Differentiation in Serum-Free Medium: Self-renewal and terminal myogenic differentiation of the O2KM line were both validated in serum-free medium;
- (vi) Compatible with Suspension Culture Systems as Embryoid Bodies: In the pluripotent state, the parental O2K and modified O2KM are resistant to anoikis and may be cultivated into embryoid bodies from single cells in suspension culture. O2KM-derived embryoid bodies may be compatible with multicellular spheroid assembly technologies such as bioprinting and micromolds for cultured meat production; and
- (vii) Autologous Contraction: O2KM terminally differentiated as skeletal muscle exhibits sarcomeric maturation and autologous contraction. Hence, external stimulation (e.g. mechanical tension, acetylcholine receptor

- 26 -

activation, electrical stimulation) may not be necessary to promote myofiber maturation.

[0086] While the invention has been described in connection with example embodiments thereof, it will be understood that the inventive method is capable of further modifications. This patent application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features herein before set forth and as follows in scope of the appended claims.

CLAIMS

What is claimed is:

1. A method for producing cultured muscle tissue, the method comprising:
modifying a self-renewing cell line of an animal species with a myogenic transcription factor to produce a myogenic-transcription-factor-modified cell line, and
inducing said modified cell line by exogenous regulation to maintain the cell line in self-renewal process or advance the cell line to myogenic differentiation process.
2. The method of claim 1, wherein the muscle tissue is of a livestock or poultry species.
3. The method of claim 2, wherein the muscle tissue is of a livestock species.
4. The method of claim 3, wherein the livestock species is porcine or bovine.
5. The method of any one of claims 1 to 4, wherein the produced muscle tissue is fit for human and non-human dietary consumption.
6. The method of any of one claims 1 to 5, wherein said self-renewing cell line is selected from the group consisting of embryonic stem cells, induced pluripotent stem cells, extra-embryonic cell lines, and somatic cell lines.
7. The method of claim 6, wherein the self-renewing stem cell line is from a livestock or poultry species.
8. The method of claim 7, wherein the self-renewing stem cell line is from a livestock species.
9. The method of claim 8, wherein the livestock species is porcine or bovine.
10. The method of any one of claims 6 to 9, wherein the self-renewing stem cell line is from any animal species intended for human or non-human dietary consumption, is any companion animal, and/or is from any animal species used for research or development of therapeutics.

- 28 -

11. The method of any one of claims 1 to 10, wherein said myogenic transcription factor is selected from the group consisting of MYOD1, MYOG, MYF5, MYF6, PAX3, PAX7, paralogs, orthologs, and genetic variants thereof.
12. The method of any one of claims 1 to 11, wherein said myogenic transcription factor is MYOD1.
13. The method of any one of claims 1 to 12 further comprising: maintaining the modified cell line in a first culture medium for undifferentiated cell stock expansion.
14. The method of claim 13 further comprising: maintaining the modified cell line in a first culture medium comprising doxycycline for cell stock expansion.
15. The method of any one of claims 1 to 14 further comprising: transferring the modified cell line into a second culture medium for lineage-specific differentiation.
16. The method of claim 15 further comprising: treating the modified cell line in a second culture medium comprising E2 for lineage-specific differentiation.
17. The method of claim 15 or 16, wherein said second culture medium further comprises a reagent for activating the canonical WNT signaling pathway, a reagent for epigenetic modulation, or a combination thereof.
18. The method of claim 17, wherein said second culture medium further comprises a reagent for activating the canonical WNT signaling pathway.
19. The method of claim 18, wherein said reagent for activating the canonical WNT signaling pathway comprises a GSK3 β inhibitor.
20. The method of claim 18, wherein said GSK3 β inhibitor is selected from one or more members of the group consisting of CHIR99021, lithium chloride, BIO, CHIR-99021, SB216763, CHIR-98014, TWS119, Tideglusib, IM-12, 1-Azakenpullone, AR-A014418, and SB415286.
21. The method of claim 20, wherein said GSK3 β inhibitor is CHIR99021.

- 29 -

22. The method of claim 17, wherein said second culture medium further comprises a reagent for epigenetic modulation.
23. The method of claim 22, wherein said epigenetic modulator is selected from one or more members of the group consisting of 5AC, RG108, Scriptaid, sodium butyrate, trichostatin A, Suberoylanilide Hydroxamic Acid, MS-275, CI-994, BML-210, M344, MGCD0103, PXD101, LBH-589, Tubastatin A, NSC3825, NCH-51, NSC-3852, HNHA, BML-281, CBHA, Salermide, Pimelic Diphenylamide, ITF-2357, PCI-24781, APHA Compound 8, Droxinostat, and SB-939, histone deacetylase paralogs, histone acetyltransferase paralogs, tet-methylcytosine dioxygenase paralogs, histone demethylase paralogs, histone methyltransferase paralogs, and DNA methyltransferase paralogs, histones, and subunits of chromatin remodeling complexes including Mi-2/NuRD and SWI/SNF.
24. The method of claim 22 or 23, wherein the epigenetic modulator is an inhibitor of DNA methylation.
25. The method of any one of claims 1 to 24, wherein the method comprises forming multinucleated myotubes.
26. The method of any one of claims 1 to 25, wherein the muscle tissue comprises skeletal muscle fibers.
27. The method of any one of claims 1 to 26, wherein the canonical WNT signaling pathway is activated by gene-editing inhibition of GSK3 β or its substrate CTNNB1.
28. An *in vitro*-produced muscle tissue made by the method of any one of claims 1 to 27.

MYO-DER-1

atggagcttctatatgcgcgcactctcgggacatagacttgaacaggcccccgaagggtctctctgtctcctttg
 agacagcagacgacttctatgatgacccgtgttttgcactcaccagacctgcgtcttttttgaggacctgga
 cccgcgccttggtgcacatgggagccctctctgaaaccggaggagcagcagcacttccctactgaggttgaa
 ccaggcccccaggcgcctcgtgaggatgagcatgttgccgcgcgcacaggggacacacdaggggtcgtctgct
 tctcttggtgacctgcagggtgctgaagcgcgaagacacacacacgtctgattggtccgaaggccgcacacatgca
 cyagggccgcgcgcctgagcacaagtgaatgaggcccttcgagagcgtcaagcgtgcacgtccagcacaacccg
 aacbaagcagctaccccgaattggagatcctgaggaagcccatccggtacatggaaggtctggcagggtctctga
 tggcgagacaggagcgcgcgcgcctggcgattctcgtggagacatgagagctgccaacctttggcccaag
 cccgctcatgatcaaacgcctctaagaagaacagccctggccctgtccctgaaggccgaacagatgggtcagc
 gccttgttgatgctgagcccccatactctattccgagtatgatcctaccagacccttcagtggaagctt
 cgaatgatgggcttaotgaccacacccctggcagacagggagctggttcacatgatcaactgggcgaagagggt
 gccaggctttgtgatttgacctccatgatcagggtccaccttctagaaatgtgcctggctagagatcctg
 atgattggtctcgtctggcgtccatggagcaccacaggggaagctactggtttgctcctaacttgctcttg
 acaggaaaccagggaatgtgtagagggcattggtggagatttccgacatgctgctggtacatcactctcg
 gttccgcgatgatgaattctgcaggagagaggattgtgtgctcccaactctattattttgcttaattctcga
 gtgtacacattctctgccagcaccctgaagtcctctggaagagaaggacccatataccaccagtccttgga
 agatcacagacactttgatccacctgatggcccaaggcaggcctgacccctgcaggcagcagcaccagcggct
 ggccagctcctcctcatcctctccacatcaggcacatgagtaacaaggcatggagcatctgtacagc
 atgaagtgcagaagacgtggtgcccctctatgacctgctgctgagagatgctggacgcccacgcctacatg
 cggccactagccgtggaggggcatccgttgaggagacggacacaaagccacttggccaatggcggctctctac
 ttcatcgcattccttgcaaaagtattacatcacgggggaggcagagggtttccctggccacaggctatccccc
 gctgccttctacgacactggacccgtgccccaggcccttggaaggagcactacagtggcgaactcagatg
 catccaggcccgctccaaactgctctgattggaatgattgattacaggggcccccccaaggcggcccccgag
 gcagaatggctacgcacaccgctactacagtgaagcggcgcgcgaggtccaggccagggaaggtgcgggct
 gtgtcagagcctcgaactgcccgttccagcatagtggagcgcctctccacagacagccccgctgcgctgcgc
 tctcttttgacagatgcaccacagagtcgctccgggtccgcacagggggcatccctaaagcgacacaga
 acagggaacccagaccccgtctcccgagcgcgcgcctcagttctcctgagggtcaaaccccccaatgcgatt
 tatcagggtgctttgga

FIG. 1





FIG. 2



DOX = Doxycycline ; E2 = 17 β -Estradiol; TRE = Tetracycline Responsive Element;
rTA = tetracycline transactivator; MBS = MyoD Binding Site

FIG. 3




FIG. 4A

FIG. 4B




FIG. 5

6/27




FIG. 6




FIG. 7




FIG. 8

9/27




FIG. 9

10/27




FIG. 10

11/27




FIG. 11

12/27




FIG. 12

13/27




FIG. 13A




FIG. 13B





FIG. 14

+5AC



-5AC




FIG. 15

16/27




FIG. 16




FIG. 17A




FIG. 17B




FIG. 18

19/27




FIG. 19A




FIG. 19B




FIG. 20A




FIG. 20B




FIG. 20C





FIG. 20D




FIG. 20F




FIG. 20E




FIG. 20G




FIG. 21A




FIG. 21C




FIG. 21B




FIG. 21D

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 14/63250

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - A01N 63/00, A01N 65/00, A61K 35/35 (2014.01)

CPC - A61K 48/00, A61K 35/12, A61K 35/32

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC(8)- A01N 63/00, A01N 65/00, A61K 35/35 (2014.01)

CPC- A61K 48/00, A61K 35/12, A61K 35/32

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
USPC- 424/93.21, 424/93.7, 424/548; CPC- A61K 48/00, A61K 35/12, A61K 35/32 (text search, term limited)

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
PatBase (PGPB, USPT, USOC, EPAB, JPAB, DWPI, TDBD), FreePatentsOnline (US Pat, PgPub, EPO, JPO, WIPO, NPL), GoogleScholar (PL, NPL); search terms: producing cultured muscle tissue myogenic transcription factor porcine bovine cow sow meat production human consumption skeletal muscle stem cell myogenic factor

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0435617 A1 (Ivarie et al.) 03 July 1991 (03.07.1991) Abstract; pg 4, ln 23-24, ln 31-34; pg 5, ln 51-53; pg 8, ln 10-44; pg 9, ln 9-17	1-5
Y	US 2011/0191871 A1 (Walsh et al.) 04 August 2011 (04.08.2011) Abstract, para [0007], [0022], [0026]-[0027], [0037], [0105], [0117], [0153], [0149]	1-5
Y	WO 1993/009236 A1 (Schwartz et al.) 13 May 1993 (13.05.1993) Abstract, pg 6, ln 24-25; ln 20-21; pg 9, ln 14-17, Fig 6-8	1

☐ Further documents are listed in the continuation of Box C.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

22 December 2014 (22.12.2014)

Date of mailing of the international search report

21 JAN 2015

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450
Facsimile No. 571-273-3201

Authorized officer:

Lee W. Young

PCT Helpdesk: 571-272-4300
PCT OSP: 571-272-7774

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 14/63250

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☒ Claims Nos.: 6-28
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.